Skip to main content

Table 1 Baseline VCA-IgA distribution in 18,286 non-nasopharyngeal carcinoma (NPC) participants by age and sex

From: Subtype distribution and long-term titer fluctuation patterns of serum anti-Epstein–Barr virus antibodies in a non-nasopharyngeal carcinoma population from an endemic area in South China: a cohort study

Sex

Age (years)

No. of participants

VCA-IgA [cases (%)]

χ2

P

1:5

1:10

1:20

≥1:40

Male

30–39

3063

2861 (93.4)

108 (3.5)

69 (2.3)

16 (0.5)

9 (0.3)

  

40–49

2196

2022 (92.1)

68 (3.1)

76 (3.5)

23 (1.0)

7 (0.3)

11.844

0.001

50–59

1740

1584 (91.0)

73 (4.2)

57 (3.3)

16 (0.9)

10 (0.6)

  

Female

30–39

5541

5225 (94.3)

139 (2.5)

129 (2.3)

27 (0.5)

21 (0.4)

  

40–49

3070

2855 (93.0)

93 (3.0)

83 (2.7)

24 (0.8)

15 (0.5)

15.475

0.000

50–59

2676

2463 (92.0)

96 (3.6)

71 (2.7)

30 (1.1)

16 (0.6)

  
  1. VCA-IgA immunoglobulin A (IgA) antibodies against viral capsid antigen of Epstein–Barr virus (EBV)